The upcoming Super Bowl ad by telehealth company Hims & Hers, promoting compounded weight-loss drugs, has sparked debate about the complexities of weight loss in the United States. Northwestern University obesity experts Drs. Justin Ryder and Veronica Johnson have weighed in on the matter.
"Yes, these drugs provide some level of risk, but I think this speaks to the desperation and larger insurance-coverage issues," said Dr. Ryder, who is an associate professor at Northwestern University Feinberg School of Medicine and vice chair of research for surgery at Ann & Robert H. Lurie Children's Hospital. He added that "these companies are preying on you, but we live in a capitalistic society."
Dr. Ryder noted that compounded versions of these medications appeal to individuals seeking weight loss solutions when their insurance does not cover FDA-approved GLP-1-based medications such as semaglutide or tirzepetide. "They’re offering them to people at rates that are high but still less than the full price of the FDA-approved versions," he stated.
However, Dr. Johnson suggested that the availability of compounded versions might soon be irrelevant: "Neither of these may be available options as compounded medications are only recommended in these situations upon a supply shortage." She mentioned that tirzepetide is no longer on the FDA drug-shortage list and semaglutide is expected to follow suit.
Both experts expressed concerns over impurities and bacteria found in compounded GLP-1-based medications. Dr. Ryder highlighted that "these drugs are not coming from a regulated manufacturer," contrasting with firms like Eli Lilly and Novo Nordisk, which face stringent regulations.
Potential risks include side effects and long-term complications, according to Dr. Ryder. Dr. Johnson emphasized uncertainty regarding potency and efficacy: "We don’t have any idea of potency and efficacy of these drugs," she said, noting reports suggesting some products might not match advertised claims.
For media inquiries or interviews with Drs. Ryder or Johnson, contact Kristin Samuelson at ksamuelson@northwestern.edu.